Pre-exposure pill shows promise protecting against HIV infection but it’s pricey

The disclosure by HIV-positive actor Charlie Sheen’s ex-girlfriend that she took a pill to prevent her from getting the disease has focused attention on Truvada.

The pill, which has been shown to reduce infection in HIV-negative partners of those with HIV by more than 90 per cent, is approved for that purpose in the U.S. but in Canada the drug’s two ingredients are approved only for use to combat HIV.

The pill’s U.S. manufacturer, Gilead Sciences, has applied for approval for Truvada as a pre-exposure prophylaxis, or PrEP.

Dr. Julio Montaner of the B.C. Centre for Excellence in HIV/AIDS said Truvada should be prescribed for sex workers or men who have sex with men but not for intravenous drug users “because there are several harm reduction strategies available” for drug users.

He said PrEP should come third in treatment options, behind treatment as prevention and condoms.

The centre is waiting to hear if the province will cover the drug under Pharmacare, as Montaner is recommending.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below